长期治疗中因血检异常停用来氟米特预后模型的开发与验证:基于临床实践研究数据链Gold和Aurum的队列研究
利用临床实践研究数据链Gold和Aurum数据开发并外部验证来氟米特因血检异常停药的预后模型。开发队列1487人3140人年,验证队列2329人5246人年。癫痫及共享医疗处方前6个月内出现血细胞减少或肝酶升高是停药的强预测因素,风险比分别为4.39(95%CI 1.74, 11.06)和3.06(2.15, 4.35)。
要点
- 开发并外部验证了一个易用的预后模型,可用于来氟米特毒性监测的风险分层。
- 癫痫及共享医疗处方前6个月内血细胞减少或肝酶升高是停药的强预测因素。
- 模型验证数据校准斜率为0.91(95%CI 0.74, 1.07),乐观校正Royston D统计量为0.73(95%CI 0.44, 1.02)。
核心结论
- 开发并外部验证了一个易用的预后模型,可能可用于来氟米特毒性监测的风险分层,并在选择治疗时对风险做出知情选择。
研究设计与样本
- 使用临床实践研究数据链Gold和Aurum数据分别进行模型开发和外部验证。
- 纳入2007年1月1日至2019年12月31日期间被处方来氟米特的参与者,从首次全科医生处方后6个月随访至结局日期、死亡、5年随访或2019年12月31日中最早者。
- 采用理论驱动和数据驱动方法确定候选预后因素,使用惩罚Cox回归开发风险方程,并通过500次bootstrap内部验证校正乐观偏倚。
- 采用多重插补处理缺失数据,从校准和区分度两方面评估模型性能。
- 开发队列1487人贡献3140人年随访,验证队列2329人贡献5246人年随访。
主要发现
- 13个候选预测因素被纳入模型。
- 癫痫及共享医疗来氟米特处方前6个月内出现血细胞减少或肝酶升高是停药的强预测因素,风险比分别为4.39(95%CI 1.74, 11.06)和3.06(2.15, 4.35)。
- 开发数据未校正和乐观校正校准斜率分别为1.00(95%CI 0.75, 1.25)和0.72(95%CI 0.47, 0.97)。
- 验证数据校准斜率为0.91(95%CI 0.74, 1.07)。
- 模型显示预后分离,乐观校正Royston D统计量为0.73(95%CI 0.44, 1.02)。
临床怎么用
- 作者认为该易用预后模型可能可用于来氟米特毒性监测的风险分层。
- 作者认为该模型可能有助于在选择治疗时对风险做出知情选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop and validate a prognostic model for LEF discontinuation with abnormal blood test results. METHODS: Data from the Clinical Practice Research Datalink Gold and Aurum were used for model development and external validation, respectively. Participants prescribed LEF between 1 January 2007 and 31 December 2019 were followed up from 6 months after the first general practitioner prescription to the earliest of date of outcome, death, 5 year follow-up or 31 December 2019. Candidate prognostic factors were ascertained using theory and data-driven approaches. Penalized Cox regression was performed to develop the risk equation, followed by internal validation using 500 bootstraps to correct for optimism. Multiple imputation was applied to handle missing data. Model performance was assessed in terms of calibration and discrimination. RESULTS: Data for 1487 and 2329 participants contributing 3140 and 5246 person-years follow-up were included in the development and validation cohorts, respectively. Thirteen candidate predictors were included in the model. Epilepsy and either cytopenia or elevated liver enzymes during the first 6 months of shared-care LEF prescription were strong predictors of drug discontinuation with a hazard ratio of 4.39 (95% CI 1.74, 11.06) and 3.06 (2.15, 4.35), respectively. The unadjusted and optimism-adjusted calibration slope in development data was 1.00 (95% CI 0.75, 1.25) and 0.72 (95% CI 0.47, 0.97), respectively. The calibration slope in validation data was 0.91 (95% CI 0.74, 1.07). The model showed prognostic separation with an optimism-adjusted Royston D statistic of 0.73 (95% CI 0.44, 1.02). CONCLUSION: We have developed and externally validated an easy-to-use prognostic model that may be used to risk stratify monitoring for LEF toxicity and to make informed choices about risks when choosing treatments.
引用
- Nakafero G, Grainge MJ, Card T, et al. Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum. Rheumatology (Oxford). 2022. PMID: 34718430. doi:10.1093/rheumatology/keab790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。